Literature DB >> 27775792

miR-143 is involved in endothelial cell dysfunction through suppression of glycolysis and correlated with atherosclerotic plaques formation.

R-H Xu1, B Liu, J-D Wu, Y-Y Yan, J-N Wang.   

Abstract

OBJECTIVE: Atherosclerosis is recognized as a chronic inflammatory disease leading to hardening of the vessel wall and narrowing of arteries. Endothelial cells (ECs) exhibit highly active glycolysis, the dysfunction of which leads to accumulation of lipids in the arterial wall and formation of atherosclerotic plaque.
MATERIALS AND METHODS: qRT-PCR was performed to compare the deregulated miR-143 between atherosclerotic plaque and normal vessel tissues. The direct target of miR-143 was verified by Western blot and luciferase assay. The metabolic enzymes in atherosclerotic plaque and normal vessel tissues were measured. HUVECs were transfected with miR-143 precursor or control microRNAs, and glucose uptake, lactate production, intracellular ATP, and oxygen consumption were measured.
RESULTS: In this study, we report a correlation between up-regulated miR-143, EC dysfunction, and atherosclerotic plaque formation. The glycolysis rate was significantly elevated in ECs, which show relatively low levels of miR-143. Importantly, miR-143 was upregulated in clinical atherosclerotic plaque samples compared with healthy arteries, suggesting that miR-143 might play important roles in the atherosclerotic plaque formation. Moreover, mRNA levels of key enzymes of glycolysis, such as HK2, LDHA, and PKM2 are significantly down-regulated in the atherosclerotic plaque samples. Overexpression of miR-143 in HUVECs suppresses glycolysis through direct targeting of HK2, leading to EC dysfunction. Restoration of HK2 expression rescues glycolysis in miR-143-overexpressing HUVECs.
CONCLUSIONS: This study provides further insight into the metabolic mechanisms involved in atherosclerotic plaque formation due to microRNAs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27775792

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

Review 1.  Pyruvate Kinase M2: a Metabolic Bug in Re-Wiring the Tumor Microenvironment.

Authors:  Mohd Rihan; Lakshmi Vineela Nalla; Anil Dharavath; Amit Shard; Kiran Kalia; Amit Khairnar
Journal:  Cancer Microenviron       Date:  2019-06-10

Review 2.  The Role of PKM2 in Metabolic Reprogramming: Insights into the Regulatory Roles of Non-Coding RNAs.

Authors:  Dexter L Puckett; Mohammed Alquraishi; Winyoo Chowanadisai; Ahmed Bettaieb
Journal:  Int J Mol Sci       Date:  2021-01-25       Impact factor: 5.923

Review 3.  CircRNA-miRNA interactions in atherogenesis.

Authors:  Kind-Leng Tong; Ke-En Tan; Yat-Yuen Lim; Xin-Yi Tien; Pooi-Fong Wong
Journal:  Mol Cell Biochem       Date:  2022-05-23       Impact factor: 3.396

Review 4.  Advances in Glycolysis Metabolism of Atherosclerosis.

Authors:  Ruhan Xu; Wei Yuan; Zhongqun Wang
Journal:  J Cardiovasc Transl Res       Date:  2022-09-06       Impact factor: 3.216

Review 5.  NLRP3 Inflammasome at the Interface of Inflammation, Endothelial Dysfunction, and Type 2 Diabetes.

Authors:  Ilona M Gora; Anna Ciechanowska; Piotr Ladyzynski
Journal:  Cells       Date:  2021-02-03       Impact factor: 6.600

6.  Single-Cell RNA Sequencing of Human Embryonic Stem Cell Differentiation Delineates Adverse Effects of Nicotine on Embryonic Development.

Authors:  Hongchao Guo; Lei Tian; Joe Z Zhang; Tomoya Kitani; David T Paik; Won Hee Lee; Joseph C Wu
Journal:  Stem Cell Reports       Date:  2019-02-28       Impact factor: 7.765

Review 7.  Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target?

Authors:  Thomas Senoner; Wolfgang Dichtl
Journal:  Nutrients       Date:  2019-09-04       Impact factor: 5.717

8.  Caloric Restriction Mimetic 2-Deoxyglucose Alleviated Inflammatory Lung Injury via Suppressing Nuclear Pyruvate Kinase M2-Signal Transducer and Activator of Transcription 3 Pathway.

Authors:  Kai Hu; Yongqiang Yang; Ling Lin; Qing Ai; Jie Dai; Kerui Fan; Pu Ge; Rong Jiang; Jingyuan Wan; Li Zhang
Journal:  Front Immunol       Date:  2018-03-02       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.